HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

hylan-B gel

hyaluronic acid based injectable dermal filler material

Also Known As:

Hylaform

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - Glycosaminoglycans: 5640
    - Hyaluronic Acid: 11384
      - hylan-B gel: 7

Experts

1.	Dahlqvist, Ake: 3 articles (12/2004 - 01/2002)
2.	Hallén, Lars: 3 articles (12/2004 - 01/2002)
3.	Barme, Greg A: 2 articles (01/2011 - 07/2010)
4.	Chittenden, Lucy: 2 articles (01/2011 - 07/2010)
5.	Gilbert, Ronald F: 2 articles (01/2011 - 07/2010)
6.	Holevas, Richard E: 2 articles (01/2011 - 07/2010)
7.	Kobashi, Luis I: 2 articles (01/2011 - 07/2010)
8.	Lizarde, Jessica: 2 articles (01/2011 - 07/2010)
9.	Mesa, Albert V: 2 articles (01/2011 - 07/2010)
10.	Ravera, John: 2 articles (01/2011 - 07/2010)

Related Diseases

1.	Cicatrix (Scar) 12/01/2002 - "Thirteen patients with glottal insufficiency caused by scar defects or paresis resulting from malignant disease were included in a nonrandomized group and were treated only with hylan B gel. " 12/01/2001 - "To assess the safety and efficacy of Sepragel sinus, a hylan B gel (cross-linked hyaluronic acid molecule), when used as a postoperative dressing after endoscopic sinus surgery as a facilitator of healing and a preventative for scarring and stenosis. "
2.	Pathologic Constriction (Stenosis) 12/01/2001 - "To assess the safety and efficacy of Sepragel sinus, a hylan B gel (cross-linked hyaluronic acid molecule), when used as a postoperative dressing after endoscopic sinus surgery as a facilitator of healing and a preventative for scarring and stenosis. "
3.	Paresis (Hemiparesis) 12/01/2002 - "Thirteen patients with glottal insufficiency caused by scar defects or paresis resulting from malignant disease were included in a nonrandomized group and were treated only with hylan B gel. " 12/01/2004 - "In a prospective trial, 70 patients with glottal insufficiency due to unilateral vocal fold paresis (n =35) or atrophy (n =35) were randomized to received either hylan B gel (n =47) or collagen (n =23) injections into 1 vocal fold. " 12/01/2002 - "Seventy patients with unilateral vocal fold paresis (n = 35) or atrophy (n = 35) were randomly assigned to receive either hylan B gel (n = 47) or collagen (n = 23) injections into one vocal fold. "
4.	Atrophy 12/01/2004 - "In a prospective trial, 70 patients with glottal insufficiency due to unilateral vocal fold paresis (n =35) or atrophy (n =35) were randomized to received either hylan B gel (n =47) or collagen (n =23) injections into 1 vocal fold. " 12/01/2002 - "Seventy patients with unilateral vocal fold paresis (n = 35) or atrophy (n = 35) were randomly assigned to receive either hylan B gel (n = 47) or collagen (n = 23) injections into one vocal fold. "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2011 - "Expanded Prostate Cancer Index Composite Bowel Bother scores decreased by 0±3 (mean±standard deviation) and 11±14 (mean±standard deviation) in patients who did and did not receive Hylaform, respectively (p=0.03). " 01/01/2011 - "Hylaform increased the separation between the prostate and rectum and decreased the mean rectal dose, thereby improving the gastrointestinal-related acute QOL of prostate cancer patients undergoing radiotherapy. " 01/01/2011 - "To test the hypothesis that cross-linked hyaluronan gel (Hylaform) does not affect the quality of life (QOL) of prostate cancer patients undergoing radiotherapy. " 07/01/2010 - "Between September 2008 and March 2009, we transperitoneally injected 9 mL of cross-linked hyaluronan gel (Hylaform; Genzyme Corporation, Cambridge, MA) into the anterior perirectal fat of 10 early-stage prostate cancer patients to increase the separation between the prostate and rectum by 8 to 18 mm at the start of radiotherapy. "

Related Drugs and Biologics

1.	Hyaluronic Acid (Hyaluronan)
2.	Collagen

Related Therapies and Procedures

1.	Injections
2.	Radiotherapy